IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) have been published in The Lancet ...
SOUTH SAN FRANCISCO, Calif., July 16, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology ...
Larimar Therapeutics Inc. LRMR said Monday it has submitted the first module of a rolling Biologics License Application to ...
Critical Path Institute's (C-Path) Data Collaboration Center (DCC) and the Friedreich's Ataxia Research Alliance (FARA) today announced the launch of the Friedreich's Ataxia Integrated Clinical ...
A team has conducted a trial on the efficacy and safety of L-arginine in treating spinocerebellar ataxia type 6 (SCA6). The findings are published in the journal eClinicalMedicine, and the team was ...
Here, we have used clinical exome sequencing with bioinformatic gene panel filtering for variant detection in cerebellar ataxia (CA) and hereditary spastic paraplegia (HSP). The prevalence rates of CA ...
Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc ...
We had reported that this disease locus was telomeric to the puratrophin-1 gene. 8 To clarify the disease locus in these patients, we reexamined the disease haplotype using microsatellite markers and ...
A research team headed by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, in collaboration with Professor Yoshitaka Nagai at Kindai ...
AJMC ®: What is your background in treating Friedreich ataxia (FA) in clinical practice and in clinical trials? KUO: I am the director of Columbia University’s ataxia center and have extensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results